Luncheon Symposium 1

Chairperson

Hyung Joon Yoo
CM Hospital, Korea

Speaker

Bukyung Kim
Kosin University, Korea

Bukyung Kim

Kosin University, Korea

• Education

Period	Affiliation	Position
– **2012-2016**	Kosin University, Graduate School	Ph.D.
– **2008-2011**	Kosin University, Graduate School	M.D.
– **1998-2004**	Kosin University College of Medicine	M.D.

• Affiliations / Experience

Period	Affiliation	Position
– **2024-Present**	Kosin University College of Medicine	Professor
– **2022-2023**	University of Massachusetts Chan Medical School	Visiting Professor
– **2012**	Aju University Hospital	Fellow
– **2007-2010**	Kosin University Gospel Hospital	Resident

• Committee Memberships

- Committee of Publication, Korean Endocrinology Society
- Direct of CDC, Korean Society of Bone and Mineral Research
- Lifetime Membership, Korean Society for the Study of Obesity

• Publications

- IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunctionassociated steatotic liver disease. Randall H. Friedline, Hye Lim Noh, Sujin Suk, Mahaa Albusharif, Sezin Dagdeviren, Suchaorn Saengnipanthkul, Bukyung Kim *et al. Nature Commucation.* (2024) 15:5506
- Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis. Hyungjune Ku, Yeonji Kim, Alvin Lyle Kim, Garam Lee, Youngsik Choi, Bukyung Kim. Endocrinology and Metabolsim. DOI:https://doi.org/10.3803/EnM.2023.1672672
- Melatonin Protects Bone Microarchitecture against Deterioration due to High-Fat Diet-Induced Obesity. Bukyung Kim, YeonJi Kim, Jae Hyun Kim, Kwangkuk Park, Hyungjune Ku, Young-Sik Choi. *Journal of Bone and Metabolism*. 2023;30(1):69-75
- Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study. Bukyung Kim, Hak Sung Lee, Hye-Jin Kim, Hyolynn Lee, In-young Lee, Soyoung Ock, Sukyoung Kwon, Sang-Soo Kang, Youngsik Choi. *Food Science and Biotechnology* (2023) 32:697–704
- Changes of Guidelines in the Management of Obese Patients With Diabetes in the Metabolic Surgery Perspective. Bukyung Kim, Kyungwon seo. *Journal of Metabolic and Bariatrictric Surgery*. 2022; 11(2): 13–19

Luncheon Symposium 1

Optimal Combination Therapy for Diabetes Management

Bukyung Kim (Kosin University, Korea)

Recent guidelines for diabetes treatment recommend early combination therapy. In addition, when selecting anti-diabetic drugs, it is recommended not simply to consider the blood sugar-lowering effect, but to take a holistic approach that considers the patient's underlying disease, demographic characteristics, and lifestyle habits. From this perspective, SGLT2i is an anti-diabetes agent that should be considered as a priority in many aspects.
Enavogliflozin is a newly developed potent SGLT-2 inhibitor. In healthy adults, the enavogliflozin 0.3mg had higher urinary glucose excretion than dapagliflozin 10mg. the potent effect of enavogliflozin could be explained by its selective and competitive inhibition of SGLT-2 compared to that of other SGLT-2 inhibitors. The strong affinity of enavogliflozin for the kidneys and its prolonged inhibitory effect on SGLT-2 may further contribute to its notable glucose-lowering efficacy.
In this lecture, we will take a close look at the results of enavogliflozin's phase 3 clinical study and pooled analysis results. This new potent SGLT2 inhibitor, Enavogliflozin, would be a good treatment option for optimal diabetes treatment.